GMAB peer analysis
Genmab (GMAB) against its competitors: price, today's move, 1-year return and market value side by side.
GMAB and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ADCT ADC Therapeutics | $1.53 | 2.68% | -66.95% | $195.33M |
| ALXO ALX Oncology | $1.22 | 0.00% | -21.29% | – |
| BNTX BioNTech | $87.75 | -0.48% | -16.17% | $22.15B |
| CGEN Compugen | $1.98 | -2.94% | 20.00% | $187.56M |
| EXEL Exelixis | $71.34 | 2.81% | 83.20% | $16.93B |
| INCY Incyte | $119.04 | -1.12% | 28.57% | $24.54B |
| IOVA Iovance | $7.94 | -6.43% | 306.92% | $3.84B |
| LEGN Legend Biotech | $21.34 | -1.34% | -33.83% | $4.21B |
| MGNX MacroGenics | $2.40 | 0.84% | 50.47% | $152.88M |
| RCUS Arcus Biosciences | $17.96 | -1.26% | -11.05% | $2.32B |
| GMAB Genmab | $55.77 | -2.25% | 94.54% | $35.09B |
- GMAB's peers: ADCT (ADC Therapeutics), ALXO (ALX Oncology), BNTX (BioNTech), CGEN (Compugen), EXEL (Exelixis), INCY (Incyte), IOVA (Iovance), LEGN (Legend Biotech).
Updated 2026-11-02 17:15 UTC